Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: Results of a prospective cohort study

Arthritis and Rheumatology

Volumn 66, Issue 4, 2014, Pages 1034-1043

  Vastert, Sebastiaan J ^a   De Jager, Wilco ^a   Noordman, Bo Jan ^a   Holzinger, Dirk ^b   Kuis, Wietse ^a   Prakken, Berent J ^a   Wulffraat, Nico M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HERPES SIMPLEX; HUMAN; HUMAN CELL; JUVENILE RHEUMATOID ARTHRITIS; LOCAL SKIN REACTION; MALE; MONOTHERAPY; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SKIN INFECTION; SYSTEMIC DISEASE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84898640609     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38296     Document Type: Article

References (48)

1. Woo P,. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2006; 2: 28-34.
2. Prakken B, Albani S, Martini A,. Juvenile idiopathic arthritis. Lancet 2011; 377: 2138-49.
3. Frosch M, Roth J,. New insights in systemic juvenile idiopathic arthritis: from pathophysiology to treatment. Rheumatology (Oxford) 2008; 47: 121-5.
4. Ramanan AV, Grom AA,. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? Rheumatology (Oxford) 2005; 44: 1350-3.
5. Vastert SJ, Kuis W, Grom AA,. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol 2009; 23: 655-64.
6. Grom AA,. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? [review]. Arthritis Rheum 2004; 50: 689-98.
7. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J,. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86.
8. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2385-95.
9. Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58: 1505-15.
10. Martini A,. Systemic juvenile idiopathic arthritis. Autoimmun Rev 2012; 12: 56-9.
11. Mellins ED, Macaubas C, Grom AA,. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011; 7: 416-26.
12. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396-406.
13. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A,. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991; 34: 1158-63.
14. De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A,. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994; 93: 2114-9.
15. De Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ,. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 2007; 66: 589-98.
16. Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2003; 48: 2622-6.
17. Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D, et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of Toll-like receptor 4, and interleukin-1β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009; 60: 883-91.
18. Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W,. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford) 2003; 42: 375-9.
19. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005; 7: R30-7.
20. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A,. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003; 142: 292-6.
21. De Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, et al. Defective phosphorylation of interleukin-18 receptor β causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009; 60: 2782-93.
22. Grom AA, Passo M,. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr 1996; 129: 630-2.
23. Ravelli A,. Macrophage activation syndrome. Curr Opin Rheumatol 2002; 14: 548-52.
24. Vastert SJ, van Wijk R, D'Urbano LE, de Vooght KM, de Jager W, Ravelli A, et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 2010; 49: 441-9.
25. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 2008; 58: 2892-6.
26. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1638-44.
27. Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford) 2012; 51: 1407-15.
28. Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011; 306: 2340-7.
29. Otten MH, Prince FH, Anink J, ten Cate R, Hoppenreijs EP, Armbrust W, et al. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Ann Rheum Dis 2013; 72: 721-7.
30. Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al, on behalf of the Societe Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pediatrie (SOFREMIP) and the Club Rhumatismes et Inflammation (CRI). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67: 302-8.
31. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 747-54.
32. Swart JF, Barug D, Mohlmann M, Wulffraat NM,. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Ther 2010; 10: 1743-52.
33. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63: 545-55.
34. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63: 465-82.
35. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
36. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A,. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
37. Wallace CA, Ruperto N, Giannini E,. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-4.
38. Wallace CA, Ravelli A, Huang B, Giannini EH,. Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol 2006; 33: 789-95.
39. De Jager W, Prakken B, Rijkers GT,. Cytokine multiplex immunoassay: methodology and (clinical) applications. Methods Mol Biol 2009; 514: 119-33.
40. Foell D, Roth J,. Proinflammatory S100 proteins in arthritis and autoimmune disease [review]. Arthritis Rheum 2004; 50: 3762-71.
41. Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, et al, and the Childhood Arthritis and Rheumatology Research Alliance CARRAnet Investigators. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2013; 65: 745-52.
42. Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al, for the Paediatric Rheumatology International Clinical Trials Organisation. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012; 64: 557-67.
43. Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2012; 71: 974-80.
44. Jelusic M, Lukic IK, Tambic-Bukovac L, Dubravcic K, Malcic I, Rudan I, et al. Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis. Clin Rheumatol 2007; 26: 1332-4.
45. Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 2010; 49: 1645-53.
46. Shimizu M, Nakagishi Y, Yachie A,. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 2013; 61: 345-8.
47. Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F,. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000; 27: 491-6.
48. Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED, Laxer RM, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000; 43: 2402-9.